E
SLNO

Ergoteles’s Soleno Therapeutics SLNO Stock Holding History

Ergoteles’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,570
Closed -$24.9K – 1715
2022
Q4 		$24.9K Buy
+12,570
New +$15.6K ﹤0.01% 1338
2021
Q4 		– Sell
-4,968
Closed -$69K – 1565
2021
Q3 		$69K Sell
4,968
-13,079
-72% -$182K ﹤0.01% 1122
2021
Q2 		$309K Buy
+18,047
New +$305K 0.01% 1057

Other funds holding SLNO

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
CP
Clayton Partners Berkeley, California $152M AUM 42.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's SLNO Position: Q1 2023 in Review

Ergoteles sold out of Soleno Therapeutics (SLNO) in Q1 2023, closing a stake of 12,570 shares — an estimated $24.9K sold.

Ergoteles first reported a position in SLNO in Q2 2021 and held it in 3 quarters. The position peaked at $309K in Q2 2021. 21 funds tracked by Wall St. Rank hold SLNO as of Q1 2023.

  • Ergoteles reported no remaining Soleno Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 12,570 Soleno Therapeutics shares in Q1 2023, an estimated $24.9K.
  • Ergoteles first reported a position in Soleno Therapeutics in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Soleno Therapeutics position peaked at $309K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.